mRNA COVID-19 Vaccine Anaphylaxis: Epidemiology, Risk Factors, and Evaluation

Centers for Disease Control and Prevention. COVID Data Tracker. https://covid.cdc.gov/covid-data-tracker/#datatracker-home. Accessed 18 Aug 2022.

Johnson AG, Amin AB, Ali AR, et al. COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of Delta and Omicron variant emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(4):132–138.

Cataldi JR, O’Leary ST. Parental vaccine hesitancy: scope, causes, and potential responses. Curr Opin Infect Dis. 2021;34(5):519–26.

Article  Google Scholar 

Luo H, Qu H, Basu R, Rafferty AP, Patil SP, Cummings DM. Willingness to get a COVID-19 vaccine and reasons for hesitancy among Medicare beneficiaries: results from a national survey. J Public Health Manag Pract. 2022;28(1):70–6.

Article  Google Scholar 

Gee J, Marquez P, Su J, et al. First month of COVID-19 vaccine safety monitoring - United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(8):283–8.

Article  CAS  Google Scholar 

Centers for Disease Control and Prevention. Information about COVID-19 vaccines for people with allergies. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/specific-groups/allergies.html. Accessed 24 Aug 2022.

King WC, Rubinstein M, Reinhart A, Mejia R. Time trends, factors associated with, and reasons for COVID-19 vaccine hesitancy: a massive online survey of US adults from January-May 2021. PLoS ONE. 2021;16(12): e0260731.

Article  CAS  Google Scholar 

Kelso JM, Greenhawt MJ, Li JT, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol. 2012;130(1):25–43.

Article  Google Scholar 

McNeil MM, Weintraub ES, Duffy J, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137(3):868–78.

Article  Google Scholar 

Maltezou HC, Anastassopoulou C, Hatziantoniou S, Poland GA, Tsakris A. Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines. Vaccine. 2022;40(2):183–6.

Article  CAS  Google Scholar 

Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021. Jama. 2021.

•• Banerji A, Norton AE, Blumenthal KG, Stone CA Jr, Phillips E. Rapid progress in our understanding of COVID-19 vaccine allergy: a cause for optimism, not hesitancy. J Allergy Clin Immunol. 2022;150(1):12–6. In this paper, the authors endeavor to review the path from news reports of vaccine allergy to the present day, in which we have specific approaches to patients. Although more research is needed, these authors propose clear, algorithmic approaches to clinical care of patients with a reported COVID-19 vaccine reaction and a reported PEG allergy.

Article  CAS  Google Scholar 

•• Copaescu AM, Rosa Duque JS, Phillips EJ. What have we learned about the allergenicity and adverse reactions associated with the severe acute respiratory syndrome coronavirus 2 vaccines: One year later. Ann Allergy Asthma Immunol. 2022;129(1):40–51. Dr. Copaescu and her co-authors do an excellent job reviewing our current understanding of the presentation and pathophysiology of COVID-19 vaccine reactions. The tables include a useful approach regarding clinical evaluation applicable for patient care.

Article  CAS  Google Scholar 

Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):46–51.

Greenhawt M, Abrams EM, Shaker M, et al. The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach. J Allergy Clin Immunol Pract. 2021;9(10):3546–67.

Article  CAS  Google Scholar 

Centers for Disease Control and Prevention. Selected adverse events reported after COVID-19 vaccination. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html. Accessed 24 Aug 2022.

Hourihane JO, Byrne AM, Blümchen K, Turner PJ, Greenhawt M. Ascertainment bias in anaphylaxis safety data of COVID-19 vaccines. J Allergy Clin Immunol Pract. 2021;9(7):2562–6.

Article  CAS  Google Scholar 

Rüggeberg JU, Gold MS, Bayas JM, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25(31):5675–84.

Article  Google Scholar 

Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report–Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391–7.

Article  Google Scholar 

Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020;13(10): 100472.

Article  Google Scholar 

Blumenthal KG, Banerji A. We should not abandon the Brighton Collaboration Criteria for vaccine-associated anaphylaxis. Ann Allergy Asthma Immunol. 2022;129(1):17–9.

Article  Google Scholar 

Hurley S, Hourihane JO. We should abandon the Brighton Collaboration Criteria for vaccine-associated anaphylaxis. Ann Allergy Asthma Immunol. 2022;129(1):20–1.

Article  Google Scholar 

•• Chu DK, Abrams EM, Golden DBK, et al. Risk of second allergic reaction to SARS-CoV-2 vaccines: a systematic review and meta-analysis. JAMA Intern Med. 2022. This meta-analysis reviews the important findings showing that most patients with reported reactions to the first dose of COVID-19 vaccines are able to tolerate second dose vaccines. This is important both in the clinical care of our patients and in our scientific understanding of the pathophysiology of the vaccine reactions.

Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med. 2021;384(7):643–9.

Article  CAS  Google Scholar 

Phillips EJ. Allergic reactions after COVID-19 vaccination-putting risk into perspective. JAMA Netw Open. 2021;4(8): e2122326.

Article  Google Scholar 

Cianferoni A. Non-IgE-mediated anaphylaxis. J Allergy Clin Immunol. 2021;147(4):1123–31.

Article  CAS  Google Scholar 

Risma KA, Edwards KM, Hummell DS, et al. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines. J Allergy Clin Immunol. 2021;147(6):2075-2082.e2072.

Article  CAS  Google Scholar 

Gold MS, MacDonald NE, McMurtry CM, et al. Immunization stress-related response - redefining immunization anxiety-related reaction as an adverse event following immunization. Vaccine. 2020;38(14):3015–20.

Article  Google Scholar 

George S, Suresh S. Vocal cord dysfunction: analysis of 27 cases and updated review of pathophysiology & management. Int Arch Otorhinolaryngol. 2019;23(2):125–30.

Article  Google Scholar 

Macy E, Pandya S, Sheikh J, et al. Population-based incidence, severity, and risk factors associated with treated acute-onset COVID-19 mRNA vaccination-associated hypersensitivity reactions. J Allergy Clin Immunol Pract. 2022;10(3):827–36.

Article  CAS  Google Scholar 

Shavit R, Maoz-Segal R, Iancovici-Kidon M, et al. Prevalence of allergic reactions after Pfizer-BioNTech COVID-19 vaccination among adults with high allergy risk. JAMA Netw Open. 2021;4(8): e2122255.

Article  Google Scholar 

Iammatteo M, Ferastraoaru D, Koransky R, et al. Identifying allergic drug reactions through placebo-controlled graded challenges. J Allergy Clin Immunol Pract. 2017;5(3):711-717.e712.

Article  Google Scholar 

Liccardi G, Senna G, Russo M, et al. Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions. J Investig Allergol Clin Immunol. 2004;14(2):104–7.

CAS  Google Scholar 

Haas JW, Bender FL, Ballou S, et al. Frequency of adverse events in the placebo arms of COVID-19 vaccine trials: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(1): e2143955.

Article  Google Scholar 

Amanzio M, Corazzini LL, Vase L, Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain. 2009;146(3):261–9.

Article  CAS  Google Scholar 

Faasse K, Huynh A, Pearson S, Geers AL, Helfer SG, Colagiuri B. The influence of side effect information framing on nocebo effects. Ann Behav Med. 2019;53(7):621–9.

Article  Google Scholar 

Blumenthal KG, Robinson LB, Camargo CA, Jr., et al. Acute allergic reactions to mRNA COVID-19 vaccines. Jama. 2021.

Kelso JM. Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines. Ann Allergy Asthma Immunol. 2021.

• Pitlick MM, Sitek AN, D’Netto ME, et al. Utility and futility of skin testing to address concerns surrounding messenger RNA coronavirus disease 2019 vaccine reactions. Ann Allergy Asthma Immunol. 2022;128(2):153–60. After prior papers had demonstrated the low utility of skin testing to excipients, skin testing to mRNA COVID-19 vaccines themselves is herein also shown to be of low utility. Both patients with no prior history of COVID-19 vaccine but high risk for allergy and patients with reported prior history of COVID-19 vaccine reactions did not have utility from COVID-19 vaccine skin testing.

Article  CAS  Google Scholar 

Tuong LC, Capucilli P, Staicu M, Ramsey A, Walsh EE, Shahzad Mustafa S. Graded administration of second dose of Moderna and Pfizer-BioNTech COVID-19 mRNA vaccines in patients with hypersensitivity to first dose. Open Forum Infect Dis. 2021;8(12):ofab507.

Banerji A, Wickner PG, Saff R, et al. mRNA Vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2020.

Picard M, Drolet JP, Masse MS, et al. Safety of COVID-19 vaccination in patients with polyethylene glycol allergy: a case series. J Allergy Clin Immunol Pract. 2022;10(2):620-625.e621.

Article  Google Scholar 

Wolfson AR, Robinson LB, Li L, et al. First-dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing. J Allergy Clin Immunol Pract. 2021;9(9):3308-3320.e3303.

Article  CAS  Google Scholar 

Shrestha P, Stone CA Jr. Allergy evaluation of messenger RNA vaccine reactions is crucial, with a specific role for polyethylene glycol testing. Ann Allergy Asthma Immunol. 2022;129(1):22–3.

Article  CAS  Google Scholar 

Frequently asked questions on the emergency use authorization for Evusheld (tixagevimab co-packaged with cilgavimab) for pre-exposure prophylaxis (PrEP) of COVID-19. https://www.fda.gov/media/154703/download. Accessed 24 Aug 2022.

Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html. Accessed 24 Aug 2022.

Kelso JM. The adverse reactions to vaccines practice parameter 10 years on-what have we learned? Ann Allergy Asthma Immunol. 2022.

Greenhawt M. True, true, and unrelated: stop routine testing to vaccine excipients for suspected vaccine allergy. Ann Allergy Asthma Immunol. 2022;129(1):24–6.

Article  Google Scholar 

留言 (0)

沒有登入
gif